John Prendergast

Dr. John K.
Prendergast is an Executive Chairman at Recce Pharmaceuticals Ltd., a President at SummerCloud Bay, Inc., a Non-Executive Chairman at Palatin Technologies, Inc., an Executive Chairman at Nejo, Inc. and a Lead Independent Director at Elusys Therapeutics, Inc. He is on the Board of Directors at Ingenex, Inc. and Elusys Therapeutics, Inc. Dr. Prendergast was previously employed as a Lead Independent Director by Scorpius Holdings, Inc., a Lead Director by MediciNova, Inc., a Chairman & Chief Executive Officer by AVAX Technologies, Inc., a Lead Director by Avigen, Inc., a Managing Director by Castle Group Ltd., an Executive Chairman by Antyra, Inc., and a Managing Director by Paramount Capital Investments LLC.
He also served on the board at Osaka Exchange, Inc. He received his graduate degree from The University of New South Wales, an MBA from Harvard University and a doctorate degree from The University of New South Wales.